870838-52-1

Basic information

• Product Name: o-bromotrifluoroacetanilide
• Synonyms: o-bromotrifluoroacetanilide
• CAS NO: 870838-52-1
• Molecular Weight: 298.059
• Mol File: 870838-52-1.mol

Chemical Properties

• CAS DataBase Reference: o-bromotrifluoroacetanilide(CAS DataBase Reference)
• NIST Chemistry Reference: o-bromotrifluoroacetanilide(870838-52-1)
• EPA Substance Registry System: o-bromotrifluoroacetanilide(870838-52-1)

Safety Data

• Hazardous Substances Data: 870838-52-1(Hazardous Substances Data)

Upstream product

• 59557-91-4 4-bromo-2-methoxyaniline 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 870838-53-2 1-{[4-bromo-2-(methyloxy)phenyl]amino}-2-propanone 
• 1438762-56-1 4-(2,2,2-trifluoroacetamido)-3-methoxyphenylboronic acid 
• 870838-56-5 1-(4-bromo-2-methoxyphenyl)-4-methyl-1H-imidazole 
• 870838-55-4 N-(4-bromo-2-methoxyphenyl)-N-(2-oxopropyl)acetamide 
• 870838-57-6 1-(4-iodine-2-methoxyphenyl)-4-methyl-1H-imidazole 
• 870838-58-7 tert-butyl [3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]propiolic acid ester 

Relevant articles and documents

PYRIDAZINE DERIVATIVES FOR INHIBITING BETA AMYLOID PEPTIDE PRODUCTION

The present invention relates to novel compounds that inhibit the production of β- amyloid peptide (1-42), processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

Cinnamide compound

The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.